Melissa D. Barnes

Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234

Krisztina M. Papp‐Wallace, Nhu Q. Nguyen, Michael R. Jacobs et al. · Journal of Medicinal Chemistry · 2018 · 150 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

<i>Klebsiella pneumoniae</i> Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering

Melissa D. Barnes, Marisa Winkler, Magdalena A. Taracila et al. · mBio · 2017 · 126 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination

Krisztina M. Papp‐Wallace, Christopher R. Bethel, J. Caillon et al. · Antimicrobial Agents and Chemotherapy · 2019 · 118 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Targeting Multidrug-Resistant <i>Acinetobacter</i> spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

Melissa D. Barnes, Vijay Kumar, Christopher R. Bethel et al. · mBio · 2019 · 117 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa

Melissa D. Barnes, Magdalena A. Taracila, Joseph Rutter et al. · mBio · 2018 · 113 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17